In The Pipeline
• SGX Pharmaceuticals has announced that Troxatyl, an investigational drug in a pivotal Phase II/III clinical trial, has been granted fast track designation by the FDA for third-line treatment of acute myeloid leukemia in adults.
• Cerexa has initiated patient enrollment in a Phase II clinical study of PPI-0903, a novel broad-spectrum, next-generation cephalosporin antibiotic with in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA).
• Cardiome Pharma Corp. and its co-development partner Astellas Pharma US have announced the initiation of an open-label safety study of intravenous RSD1235 for the acute treatment of atrial fibrillation.
SGX Pharmaceuticals has announced that Troxatyl, an investigational drug in a pivotal Phase II/III clinical trial, has been granted fast track designation by the FDA for third-line treatment of acute myeloid leukemia in adults.Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.